Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Sanofi SA, of Paris, said detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled phase III studies evaluating Dupixent (dupilumab) in adult patients with inadequately controlled moderate to severe atopic dermatitis (AD), were published in The New England Journal of Medicine.